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ABSTRACT
ST6GalNAc-I, the sialyltransferase responsible for sialyl-Tn (sTn) synthesis, has 
been previously reported to be positively associated with cancer aggressiveness. Here 
we describe a novel sTn-dependent mechanism for chemotherapeutic resistance. We 
show that sTn protects cancer cells against chemotherapeutic-induced cell death 
by decreasing the interaction of cell surface glycan receptors with galectin-3 and 
increasing its intracellular accumulation. Moreover, exogenously added galectin-3 
potentiated the chemotherapeutics-induced cytotoxicity in sTn non-expressing cells, 
while sTn overexpressing cells were protected. We also found that the expression 
of sTn was associated with a reduction in galectin-3-binding sites in human gastric 
samples tumors. ST6GalNAc-I knockdown restored galectin-3-binding sites on the cell 
surface and chemotherapeutics sensibility. Our results clearly demonstrate that an 
interruption of O-glycans extension caused by ST6GalNAc-I enzymatic activity leads 
to tumor cells resistance to chemotherapeutic drugs, highlighting the need for the 
development of novel strategies to target galectin-3 and/or ST6GalNAc-I.
INTRODUCTION
Modification of cell surface glycosylation is a 
common feature of cancer cells [1, 2]. Over the last few 
years, several studies have demonstrated the importance 
of altered glycosylation in tumor progression and have 
deepened our understanding in the molecular mechanisms 
that influence tumor behavior. Because tumor-specific 
carbohydrate antigens are exclusively expressed by cancer 
cells and are usually associated with a poor prognosis, they 
have been commonly used in the clinic as tumor markers 
[4, 5]. The glycans found in human cells, typically undergo 
glycosylation in the endoplasmic reticulum-Golgi pathway, 
and are mainly attached to the protein via an Asn residue 
(for N-glycans) or, they can be attached by a GalNAc 
residue in the hydroxyl group of a Ser or Thr residue on 
the peptide sequence (Tn antigen), for O-glycans [6]. This 
simplest O-glycan, Tn antigen, can be further converted 
to a core 1 structure (T antigen) by the addition of a β1,3-
galactose extension or to a core 3 structure by the addition 
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of β1,3-GlcNAc. Core 1 structure can be further branched 
by C2GnT1 to form core 2 that can be further modified to 
poly-N-acetyllactosamine structures [7].
Shortened or truncated O-glycans seem to be a 
frequent modification associated with tumor development 
[8]. These modifications, which include antigen T/Tn, sialyl 
Thomsen-nouvelle antigen (sialyl-Tn) and sialyl Lewis 
antigens (sLe) can affect cell surface receptors properties 
such as, binding, activity and stability; regulate cell-cell 
and cell-ECM adhesion; or increase cell proliferation and 
evasion of the immune system [3]. ST6GalNAc-I is the 
sialyltransferase responsible for the synthesis of sialyl-
Tn (sTn) [9], a glycan structure that cannot be further 
processed, which blocks the posterior elongation of the 
O-glycan chains [10]. Altered expression of sTn antigen in 
cancer cells has been shown to be a consequence of multiple 
mechanisms. Indeed, it was reported that overexpression 
of ST6GalNAc-I in gastric, breast, prostate and bladder 
cell lines induced the expression of sialyl-Tn, indicating a 
fundamental role for this enzyme in sTn biosynthesis [10–
13]. Moreover, it has been demonstrated that mutations and 
loss of heterozygoty of the COSMC gene, which encodes 
a chaperone protein required for the correct activity of 
the C1Ga1T1 enzyme (that catalyzes the T antigen), were 
associated with sialyl-Tn expression in colon and melanoma 
cell lines and in sTn positive cervical cancer tissue [14–
16]. Additionally, hypermethylation of COSMC gene 
was also found to be associated with increased truncated 
O-glycans in pancreatic cancer cells [17]. Re-localization 
of GalNAc-T from the Golgi to the endoplasmic reticulum 
[18], a reorganization of glycosyltransferase topology [19], 
and fluctuations in cellular pH [20, 21] were also found to 
favor shorter glycan chain lengths such as sTn.
Although the association between ST6GalNAc-I and 
the expression of sTn is still not fully clear, sTn antigen 
is highly expressed in most gastric [22], colorectal [23], 
ovarian [24], breast [25] and pancreatic carcinomas [26] 
whereas no expression is observed in the respective normal 
tissues. The positive correlation of sTn with carcinoma 
aggressiveness and poor prognosis has motivated the 
research on sialyl-Tn role in cancer cell biology. Recently, 
Radhakrishnan et al. showed that truncated O-glycans, such 
as sTn, could directly induce oncogenic characteristics to 
tumor cells, including increased proliferation, loss of tissue 
architecture, disruption of basement membrane adhesion 
and invasive growth, in a pancreatic model [17]. Likewise, 
in a gastric cancer model, it was found that sTn antigen 
was able to induce a more aggressive cell behavior, such 
as decreased cell–cell aggregation and increased ECM 
adhesion, migration and invasion [22]. Sialyl-Tn was 
also found to be responsible for morphological changes, 
impaired proliferation, and decreased migration on 
fibronectin and hyaluronic acid strata in a mouse mammary 
carcinoma cell line [27]. Furthermore, in a murine model, 
the overexpression of sTn in gastric cancer cells increased 
their intraperitoneal metastatic ability resulting in shortened 
survival time of the mice [28]. Recently, ST6GalNAc-I 
silencing was associated with a reduction in proliferation, 
migration and invasion of hepatocarcinoma cell through 
PI3K/AKT/NF-κB pathway [29].
Still, the role of ST6GalNAc-I in chemoresistance 
remains to be explored. Although the exact mechanism 
by which sialyl-Tn controls the cancer cell biology is not 
known, it has been hypothesized that sTn may interfere 
with the interaction of glycan-binding proteins with 
glycosylated cell surface proteins, thus promoting tumor 
progression. So far, this hypothesis has never been studied.
Galectin-3 (gal-3) is a β-galactoside-binding protein 
that binds a wide array of glycan-containing glycoproteins 
expressed on the cell surface, thus regulating the activation 
status of the cell [30]. Similar to ST6GalNAc-I, gal-
3 plays an important role in cancer biology. It has been 
reported that gal-3 expression is increased in tumor cells 
including breast [31], colon [32], pancreatic [33], thyroid 
[34] and gastric [35] when compared to normal cells. The 
alteration of gal-3 expression is correlated with tumor 
aggressiveness and acquisition of a metastatic phenotype, 
indicating that gal-3 is able to increase tumor development 
and influence the progression of the disease.
Gal-3 functions through both intracellular and 
extracellular mechanisms. Intracellularly, gal-3 was 
found to have an important role in protecting cells against 
apoptosis and was reported to decrease BT549 human 
breast carcinoma cells resistance to cisplatin, anthracycline, 
adriamycin and 5-FU-induced apoptosis [36]. Upon 
secretion to the extracellular milieu via a non-classical 
pathway [37], galectin-3 can bind to cell surface glycans, 
increasing cell signaling and cell-matrix interactions, for 
example, through α1β1 integrin [38, 39]. Extracellularly, 
gal-3 has been shown to preferentially bind to galactose-
β1-4-N-acetylglucosamine (LacNAc) units, which can 
be found in the branches of N- or O-linked glycans [40]. 
Among the branched N-glycans, the β1,6-GlcNAc-
branched product of MGAT5 is the acceptor for additional 
extension with N-acetyllactosamine units, which is the 
preferred ligand for galectin-3 [40, 41]. Several groups 
have reported that N-linked α2-6-sialylation mediated by 
the ST6Gal-I enzyme, completely blocked recognition by 
gal-3 [42, 43] whereas α2-3-sialylated glycans were well 
tolerated [41, 44]. Still, whether the role of other sialylated 
structures, such as truncated O-glycans like sTn, can 
contribute to block gal-3 binding to the cell surface has 
never been studied so far. Moreover, to date, no connection 
has been made between the intracellular anti-apoptotic 
function of galectin-3 and the expression of sialylated 
O-glycans.
In the present study we demonstrated that the 
overexpression of sTn led to a decrease in gal-3 cell 
surface binding sites in cancer cells that leads to an 
accumulation of gal-3 in the intracellular environment, 
which can account for the chemotherapeutic resistance 
observed in ST6GalNAc-I-overexpressing tumor cells. 
Although exogenously added gal-3 did not induce tumor 
cell death, it showed a potentiating effect on drug-induced 
Oncotarget83572www.impactjournals.com/oncotarget
cell death. These findings were further validated in human 
gastric cancer samples, showing that gal-3-binding sites 
expression correlated negatively with sialyl-Tn levels. Our 
results suggest that sTn aberrant expression in O-glycans 
increases gastric carcinoma cells drug resistance by 
shifting gal-3 subcellular localization.
RESULTS
Overexpression of ST6GalNAc-I leads to 
sialyl-Tn expression and confers resistance to 
chemotherapeutic drugs in MKN45 gastric 
cancer cells
The human gastric carcinoma cell line (MKN45), 
which shows very little expression of sTn [10], was 
initially transfected with the full length of ST6GalNAc-I or 
empty vector (Mock). After clonal selection, we found that 
ST6GalNAc-I-expressing clones #3, #5 and #7 displayed 
increased ST6GalNAc-I mRNA levels (Supplementary 
Figure S1A) and sTn antigen levels, as observed by flow 
cytometry (Supplementary Figure S1B) in comparison 
with Mock cells. The subsequent experiments were 
performed with the clone #5 (named ST6GalNAc-I) since 
it presented the highest increase of sialyl-Tn expression 
and ST6GalNAc-I mRNA levels (Figures 1A-1C). Mock 
and ST6GalNAc-I-overexpressing cells were then treated 
with 12.5 μM of cisplatin for 48h and flow cytometry 
analysis showed that Mock cells exhibited increased 
activation of caspase-3/7 in response to cisplatin in 
comparison with ST6GalNAc-I-overexpressing cells 
(Figure 1D). Treatment of cells with increasing doses 
of cisplatin or 5-fluorouracil (5-FU) revealed that 
ST6GalNAc-I-overexpressing cells were more resistant 
to the cytotoxic effect of cisplatin and 5-FU than Mock 
cells, with IC50 values of 5.8 μM (cisplatin) and 152 μM 
(5-FU) for ST6GalNAc-I-overexpressing and 3.5 μM 
(cisplatin) and 25 μM (5-FU) for Mock cells (Figures 1E-
1H). Additionally, Mock or ST6GalNAc-I-overexpressing 
cells were grown into spheroids, which replicate important 
features of tumors in vivo, and treated with cisplatin once 
spheroids reached approximately a volume of 0.5 mm3. 
Although Mock cells formed significantly bigger spheroids 
than ST6GalNAc-I-overexpressing cells, Mock spheroids 
presented a significant volume reduction in the presence 
of cisplatin compared to ST6GalNAc-I-overexpressing 
spheroids (Figure 1I and 1J). These results indicate that 
ST6GalNAc-I-overexpressing cells are more resistant to 
chemotherapeutic drugs than Mock cells.
Sialyl-Tn expression induces galectin-3 shift into 
the intracellular compartment
We next observed that Mock cells treated 
with cisplatin displayed increased cell surface and 
supernatants levels of gal-3 (Figures 2A-2C) in 
comparison with ST6GalNAc-I-overexpressing cells. 
By flow cytometry, ST6GalNAc-I-overexpressing 
cells presented reduced levels of cell surface gal-3 in 
comparison to Mock cells (Figure 2D). These results 
were confirmed by immunofluorescence microscopy 
(Figure 2E) and the same findings were observed for 
ST6GalNAc-I low-expressing clones (Supplementary 
Figure S1C). We next incubated cells with Gal-3-Dy488 
in the presence or absence of lactose (a competitive 
gal-3 CRD inhibitor) and found that ST6GalNAc-I-
overexpressing cells displayed a substantial reduction 
in gal-3-binding sites compared to Mock cells as 
observed by flow cytometry analysis (Figure 2F and 
Supplementary Figure S1D) and immunofluorescence 
microscopy (Figure 2G). Surprisingly, no changes in the 
total level of endogenous gal-3 were observed between 
both cells by flow cytometry analysis (Supplementary 
Figure S1E) or RT-PCR (Supplementary Figure 
S1F). Taken together, these data indicate that the 
overexpression of ST6GalNAc-I induces a cell surface 
to intracellular shift of gal-3 protein.
Sialyl-Tn expression reduces the availability of 
galectin-3-binding sites despite the presence of 
complex-type N-glycans
We next evaluated the glycosylation signature 
of Mock and ST6GalNAc-I-overexpressing cells 
using a panel of plant lectins that recognize specific 
glycan structures, including those that are relevant 
for gal-3 binding. We found that ST6GalNAc-I-
overexpressing cells presented increased binding to 
L-phythemagglutinin (L-PHA), which recognizes 
tri- and tetraantennary complex-type N-glycans, in 
comparison to Mock cells (Figure 3A). The binding 
of ECA lectin (Erythrina Cristagalli) to unsialylated 
terminal galactosyl (β-1,4) N-acetylglucosamine was 
decreased in ST6GalNAc-I-overexpressing cells (Figure 
3B), while the binding of MAL-II (Maackia amurensis 
agglutinin), which recognizes α2-3-sialic acid linkages, 
was increased in ST6GalNAc-I-overexpressing cells 
(Figure 3C). No difference in the binding of PNA lectin 
(Arachis hypogaea, that recognizes galactosyl (β-1,3) 
N-acetylgalactosamine present in O-glycans), was found 
between Mock and ST6GalNAc-I-overexpressing cells 
(Figure 3D). We also observed that Sambucus nigra 
agglutinin (SNA), a lectin that recognizes α2-6-linked 
sialic acid present in N-glycans, increased its binding 
to ST6GalNAc-I-overexpressing cells in comparison 
to Mock cells (Figure 3E). Altogether, our findings 
indicate that the O-glycan modification provided by 
ST6GalNAc-I overexpression can decrease gal-3 
binding to the cellular surface also by interfering directly 
or indirectly with other sialyltransferases, which provide 
additional evidence about the importance of O-glycans 
sialylation for gal-3 binding.
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Figure 1: Sialyl-Tn confers chemotherapeutic resistance. A. Immunoblot of sialyl-Tn and galectin-3 in Mock and ST6GalNAc-
I-overexpressing cells. β-actin was used as a loading control. B. mRNA levels of ST6GalNAc-I in Mock and ST6GalNAc-I cells. Values 
were normalized to β-actin. C. Flow cytometry histogram and mean fluorescence intensity (MFI) quantification of sialyl-Tn in Mock and 
ST6GalNAc-I cells. D. Flow cytometry dot plot and histogram of caspase 3/7 activation in Mock and ST6GalNAc-I-overexpressing cells 
undergoing apoptosis by treatment with cisplatin (12.5 μM). E-H. SRB assay showing the cells viability under the treatment of (E) cisplatin 
or (G) 5-FU and determined as a percentage of viable cells relative to control (cells with no drug treatment). F and H. are the average of 
IC50 values. I and J. (I) Growth curve of Mock (circle) or ST6GalNAc-I-overexpressing (triangle) cells spheroids. Cisplatin (50 μM) was 
added to spheroid culture and day 4 and the spheroid volume was measured until day 9. (J) Representative images of MKN45 spheroids at 
day 1, 4 and 9, Bar=400 μm). Data are representative or are the mean ± SEM of three independent experiments, **p < 0.01, ***p < 0.001.
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Figure 2: Sialyl-Tn inhibits galectin-3 binding to cellular surface. A and B. (A) Flow cytometry analysis of Mock and 
ST6GalNAc-I-overexpressing cells stained with anti-galectin-3 antibody after cultured in the presence of cisplatin (12.5 μM and 25μM) 
and (B) mean fluorescence intensity (MFI) due to galectin-3 staining. C. Quantification by ELISA of galectin-3 in culture supernatants 
of Mock and ST6GalNAc-I-overexpressing cells treated with cisplatin (12.5 μM and 25 μM, as indicated) for 48h. D. Mean fluorescence 
intensity (MFI) of cell surface galectin-3 in Mock and ST6GalNAc-I-overexpressing cells. E. Representative immunofluorescence 
images of Mock and ST6GalNAc-I-overexpressing cells stained with anti-galectin-3 and anti-sialyl-Tn antibodies (Bar=5 μm). F. Mean 
fluorescence intensity (MFI) of galectin-3-binding sites by using Gal-3Dy488 staining in Mock and ST6GalNAc-I-overexpressing cells. G. 
Representative immunofluorescence images of Mock and ST6GalNAc-I-overexpressing cells stained with Gal-3-Dy488 and anti-sialyl-Tn 
antibody (Bar=5 μm). Data are representative of three independent experiments (A, D-G), or are the mean ± SEM (B and C), *p<0.05; 
**p<0.01; ****p<0.0001. See also Figure S1.
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Sialyl-Tn expression protects cells from galectin-
3-enhancing effect on the anticancer activity of 
chemotherapeutic drugs
Subsequently, we treated Mock and ST6GalNAc-
I-overexpressing cells with recombinant human gal-3 (2 
μM) and found that gal-3 treatment alone had no effect 
on cell death (Figure 4A, Supplementary Figure S2A), the 
ability to form colonies (Figure 4B) or on the cleavage 
of PARP and phosphorylation of H2AX (γ-H2AX) 
(Figure 4C) in both cells. However, the combination of 
both gal-3 and cisplatin led to a significant increase in the 
percentage of cell death (Figure 4A, Supplementary Figure 
S2A), reduction in the number colonies (Figure 4B) and 
increased PARP cleavage and γ-H2AX phosphorylation 
(Figure 4C) in Mock cells in comparison to cisplatin 
alone, whereas no changes were observed in ST6GalNAc-
I-overexpressing cells. The potentiating effect of gal-3 
Figure 3: Evaluation of the binding of L-PHA, ECA, MAL-II, PNA and SNA lectins in Mock and ST6GalNAc-I-
overexpressing cells. Flow cytometry histograms and mean fluorescence intensity (MFI) of Mock and ST6GalNAc-I-overexpressing 
cells detected with the biotinylated lectins A. L-PHA, B. ECA, C. MAL-II, D. PNA and E. SNA (grey solid) or with Cy5-conjugated 
streptavidin alone (filled black). Data are representative images of three independent experiments or are the mean ± SEM, n=3. *p < 0.05, 
*p < 0.01, ***p < 0.001.
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on cellular death was inhibited by lactose and therefore, 
dependent on gal-3 carbohydrate binding domain. We 
next evaluated the survival of Mock or ST6GalNAc-I-
overexpressing cells treated with cisplatin or 5-FU in the 
presence of gal-3 or its N-terminally truncated form (gal-
3C). Mock cells incubated with gal-3 displayed a higher 
susceptibility to the cytotoxic effect of cisplatin (Figure 
4D and Supplementary Figures S2B and S2C) or 5-FU 
(Figure 4E and Supplementary Figures S2D and S2E) 
as compared to cisplatin treatment alone. Contrastingly, 
gal-3C did not affect cisplatin or 5-FU cytotoxic 
effect in Mock cells. Neither gal-3 nor gal-3C had any 
influence on the cytotoxic effect of cisplatin and 5-FU in 
ST6GalNAc-I-overexpressing cells (Figure 4D and 4E). 
Our results demonstrate that although extracellular gal-
3 does not directly induce cells death, it potentiates the 
effect of chemotherapeutic drugs in cells bearing gal-3-
binding sites.
Sialyl-Tn-induced intracellular shift of galectin-3 
protects cells from cisplatin induced cell death
Since intracellular gal-3 has an important role in 
protecting cells against apoptosis [45], we subsequently 
knockdown gal-3 in Mock and ST6GalNAc-I-
overexpressing cells using shRNA for gal-3 (Figure 5A). 
Downregulation of gal-3 had no effect on cisplatin-induced 
cell death in Mock cells (Figure 5B and Supplementary 
Figure 4: Galectin-3 increases Mock cells susceptibility to cisplatin. A. Quantification of % of cell death by measuring propidium 
iodide incorporation, assessed by flow cytomety, in Mock and ST6GalNAc-I-overexpressing cells cultured for 48h with cisplatin and 
galectin-3 in the presence or absence of lactose. B. Clonogenic assay of Mock and ST6GalNAc-I-overexpressing cells after cultured 
for 48h with cisplatin and galectin-3. C. Immunoblot of PARP, cleaved PARP and γ-H2AX, as indicated, in Mock and ST6GalNAc-I-
overexpressing cells cultured with cisplatin and galectin-3 in the presence or absence of lactose for 16h and 24h. β-actin was used as a 
loading control. D and E. IC50 values for Mock and ST6GalNAc-I-overexpressing cells cultured 48h with (D) cisplatin or (E) 5-FU in 
the presence or absence of gal-3 or gal-3C. Data are the mean ± SEM, n=3 (A, B, D and E) or are representative of three independent 
experiments (C). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S2.
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Figure S3A). On the other hand, ST6GalNAc-I-shRNA-
Gal-3 cells presented an increased percentage of cell 
death, similar to Mock levels, when treated with cisplatin. 
We further evaluated cisplatin and 5-FU cytotoxicity 
and showed that gal-3 inhibition significantly increased 
cisplatin (Figures 5C-5D and Supplementary Figure S3B-
S3E) and 5-FU (Figures 5E-5F and Supplementary Figure 
S3F-S3I) cytotoxicity in both Mock and ST6GalNAc-I-
overexpressing cells in comparison to scrambled cells. 
Incubation with gal-3 increased Mock-scrambled cells 
susceptibility to cisplatin or 5-FU as compared to cisplatin 
treatment alone, whereas gal-3C had no effect in cells 
viability (Figure 5C and 5E). Gal-3 and gal-3C had no 
effect in the viability of ST6GalNAc-I overexpressing 
cells (Figure 5D and 5F). Collectively, our results suggest 
that overexpression of ST6GalNAc-I leads to an increase 
in cytoplasmic galectin-3 expression, which results in 
resistance to drug-induced apoptosis.
ST6GalNAc-I knockdown restores galectin-
3-binding sites and sensitizes tumor cell to 
cisplatin-induced cell death
To further establish a role for ST6GalNAc-I in gal-3 
binding and cisplatin sensitivity, we treated ST6GalNAc-
I-overexpressing cells with two different dsRNA (RNAi 
Figure 5: Intracellular galectin-3 protects cells from chemotherapeutic-induced cytotoxicity. A. Immunoblot of galectin-3 
in Mock and ST6GalNAc-I-overexpressing cells transduced with viral particles containing scrambled or shRNA-Gal-3. β-actin was used as 
a loading control. B. Quantification of % of cell death after culturing Mock and ST6GalNAc-I with cisplatin (12.5μM) for 48h. Cells were 
assayed by propidium iodide and flow cytometry. C-F. IC50 values for Mock and ST6GalNAc-I-overexpressing cells transduced with viral 
particles containing scrambled or shRNA-Gal-3 after culture with cisplatin (C and D) or 5-FU (E and F) and galectin-3 or galectin-3C. Data 
are representative of three independent experiments (A), or are the mean ± SEM, n=3 (B-F). *p < 0.05, ***p < 0.001, ****p < 0.0001. See 
also Figure S3.
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1 and RNAi 2). We observed a reduction of 45% (RNAi 
1) and 60% (RNAi 2) in ST6GalNAc-I mRNA levels 
(Figure 6A) and decreased levels of sTn (63% and 58%, 
respectively) (Figure 6B) in comparison with scramble-
treated cells. We next found that ST6GalNAc-I inhibition 
restored the levels of gal-3-binding sites (Figure 6C) 
and cell surface gal-3 (Figure 6D) to the levels found 
in Mock levels. Consistent with our previous results 
(Supplementary Figure S1E and S1F), no changes in 
the total mRNA levels of gal-3 were found in Mock, 
Figure 6: ST6GalNAc-I knockdown increases galectin-3-binding sites and cisplatin-induced cell death. A. mRNA levels 
of ST6GalNAc-I in Mock, ST6GalNAc-I and ST6GalNAc-I knockdown cells. Values were normalized to β-actin. B-D. Flow cytometry 
histogram and mean fluorescence intensity (MFI) quantification of (B) sialyl-Tn (grey solid), (C) Gal-3-Dy488 (grey solid) and (D) cell 
surface gal-3 (grey solid) in Mock, ST6GalNAc-I and ST6GalNAc-I knockdown cells. Negative control: filled black. E and F. mRNA 
levels of (E) galectin-3 and (F) ST6Gal-I in Mock, ST6GalNAc-I and ST6GalNAc-I knockdown cells. Values were normalized to β-actin. 
G. Quantification of the % of cell death after culturing Mock, ST6GalNAc-I and ST6GalNAc-I knockdown cells with cisplatin (12.5μM) in 
the presence or absence of galectin-3 for 48h. Cells were assayed by propidium iodide and flow cytometry. Data are representative of two 
independent experiments or are the mean ± SEM, n=3. *p < 0.05, *p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S4.
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ST6GalNAc-I-overexpressing and ST6GalNAc-I-
knockdown cells (Figure 6E). Additionally, we found 
that cisplatin treatment (alone or in combination with 
galectin-3) induced higher mortality rate in ST6GalNAc-I 
knockdown cells in comparison with scramble-treated cells 
(Figure 6F). The susceptibility to cisplatin-induced cell 
death in ST6GalNAc-I knockdown cells was comparable 
to Mock cells. Finally, we evaluated the mRNA levels 
of ST6Gal-I enzyme, a N-linked α2-6 sialyltransferase, 
to rule out its interference in blocking gal-3-binding 
to the cell surface. Even though the levels of ST6Gal-I 
mRNA were increased in ST6GalNAc-I-overexpressing 
cells in comparison to Mock cells (Figure 6G), they 
were not altered between ST6GalNAc-I knockdown and 
ST6GalNAc-I-overexpressing cells (Figure 6G). These 
results demonstrate that knocking down ST6GalNAc-I 
expression is effective in restoring gal-3-binding, gal-
3 cell surface expression and in increasing cisplatin 
sensitivity in tumor cells.
Sialyl-Tn-expressing tumor xenografts have an 
increased growth rate and reduced galectin-3-
binding sites
We subsequently inoculated Mock or ST6GalNAc-
I-overexpressing cells subcutaneously in Balb/c nude 
mice and observed that ST6GalNAc-I-overexpressing 
tumors had a significantly higher growth rate than Mock-
derived tumors (Figure 7A). At the end of the experiment 
(day 20) tumors were collected and no differences were 
found between Mock and ST6GalNAc-I-derived tumors 
with regard to gal-3 mRNA levels (Figure 7B) or protein 
expression assessed by immunohistochemical staining 
(Figure 7C). Furthermore, using a human recombinant 
Figure 7: Sialyl-Tn increases tumor growth and decreases galectin-3-binding sites in vivo. A. Tumor growth of Mock 
and ST6GalNAc-I overexpressing cells in Balb/c nude mice. B. mRNA levels of galectin-3 in Mock and ST6GalNAc-I derived tumors. 
Values are normalized to β-actin mRNA expression. C. Immunohistochemical staining of galectin-3, galectin-3-binding sites (hrGal-3/AP) 
and sialyl-Tn in Mock and ST6GalNAc-I-derived tumors. Black arrows show no co-localization of galectin-3-binding sites with sialyl-
Tn. Representative images are shown, bar=20 μm. Data are the mean + SEM (A and B), n=3, or are representative of three independent 
experiments, five animals per group (C). ****p<0.0001.
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gal-3 protein fusioned with bacterial alkaline phosphatase 
(hrGal3/AP) we found that gal-3-binding sites were 
lower in ST6GalNAc-I-derived tumors in comparison to 
Mock (Figure 7C). Interestingly, we observed that cells 
expressing sTn were unable to bind hrGal-3/AP and the 
opposite was also true (shown by arrows in Figure 7C). 
Thus, ST6GalNAc-I overexpression confers a selective 
growth advantage to the tumors, which was associated to 
a reduced availability of gal-3-binding sites in vivo.
Expression of sialyl-Tn is associated with a 
reduction in galectin-3-binding sites in human 
gastric tumors
We further evaluated whether the negative 
correlation between sTn expression and galectin-3- 
binding sites could be found in the normal adjacent 
mucosa, intestinal metaplasia (IM), tumor and associated 
metastasis in human gastric samples. Gastric samples were 
classified according to the histological types [24] and the 
percentage of positive galectin-3, sTn and galectin-3-
binding sites stained tumor cells were quantified (Table 
S1). Galectin-3 expression was found to be strongly 
expressed in IM and moderately expressed in normal 
adjacent mucosa (Figure 8A). In the tumor, gal-3 was 
found to be expressed in 39/40 (97.5%) of the samples 
and to be present in all 6 gastric cancer-derived metastasis 
samples. Galectin-3-binding sites were detected in normal 
adjacent mucosa but not in IM (Figure 8A) and were 
inhibited by lactose, a gal-3 inhibitor (Supplementary 
Figure S5). In contrast, sTn was completely absent in 
normal adjacent mucosa and expressed in IM. In the 
tumor, gal-3-binding sites were detected in 40/40 (100%) 
of samples and sTn was expressed in 31/40 (77.5%) of 
gastric cancer cases, however, gal-3-binding sites and sTn 
were never co-localized with each other. Also, a negative 
correlation between gal-3-binding sites and sTn expression 
was also observed in gastric cancer-derived metastasis, 
(Figure 8A) that was further confirmed in a double 
immunofluorescence assay using anti-sTn antibody and 
human recombinant gal-3 previously labeled with -Dy488 
(Gal-3-Dy488) (Figure 8B). These results strongly suggest 
an important role for sialyl-Tn in reducing galectin-3-
binding sites in gastric tumor samples.
DISCUSSION
The aberrant expression of sialylated proteins is 
a common feature of cancer cells, which allows cells 
to escape from the immune surveillance and increases 
migration and metastasis [8, 22, 25].
Recent studies have provided evidences that α2-6 
sialylation of N-linked glycans by the action of ST6Gal-I 
enzyme can contribute to restrain cell death and to 
increase therapy resistance in cancer. For example, α2-6 
sialylation of Fas and tumor-necrosis factor receptor-1 
(TNFR1) by ST6Gal-I inhibited Fas-mediated cell death 
in colon carcinoma cells [46] and protected macrophages 
from apoptosis [47]. ST6Gal-I overexpression in ovarian 
cancer cell was reported to confer resistance to cisplatin 
treatment, while ST6Gal-I knockdown sensitized cells 
to cisplatin [48]. Additionally, ST6Gal-I was highly 
expressed in cisplatin-resistant cells [48] and was 
associated with increased cancer stem cell resistance to 
irinotecan and gemcitabine in colon and ovarian cancer 
cell lines, respectively [49, 50]. Besides chemotherapy, 
Lee et al., demonstrated that ST6Gal-I expression 
contributed to colon cancer cells radiation-resistance, still, 
this effect could be reversed after knockdown of ST6Gal-I 
or expression of NEU2 sialidase [51, 52]. Expression of 
other N-linked sialyltransferases, such as ST8Sia I and 
ST3Gal-I, ST3Gal-II, ST3Gal-III, and ST3Gal-IV were 
also increased following radiation exposure, however, their 
role in radiation resistance remains to be investigated [51]. 
These findings provide several evidences that N-linked 
sialylation increases resistance to chemo- and radiation 
therapy, however so far no study has addressed the role 
O-linked sialylation in chemotherapy resistance. In this 
study we demonstrate that ST6GalNAc-I overexpression 
conferred chemoresistance of gastric tumor cells by 
interfering with gal-3 subcellular localization. To the best 
of our knowledge, this is the first report to demonstrate 
the involvement of ST6GalNAc-I-induced sialylation in 
chemoresistance.
In fact, the specific modification of cell surface 
proteins with O-glycans has been shown to regulate 
ligand-receptor binding and cell signaling [53]. For 
example, MUC1 (mucin 1), CD44 and integrin β1 
have been identified as sialyl-Tn carrier proteins, all 
playing important roles in cell adhesion, migration and 
chemoresistance [10, 12, 22, 27]. MUC1 has been show 
to attenuate the apoptotic response to DNA damage 
conferring resistance to chemotherapeutic drugs such 
as cisplatin [54]. Similarly, integrin β1 has been shown 
to block apoptosis induced by cisplatin via ERK and 
MAP kinase [55, 56] and CD44 molecule has been show 
to promote PI-3 kinase-mediated oncogenic signaling 
and cisplatin resistance in cancer cells [57]. Since gal-
3 increases the endocytosis of MUC1 [58], integrin β1 
[54] and CD44 [59], high levels of sTn on the tumor cell 
surface might be a mechanism to block gal-3-mediated 
endocytosis, thus increasing the stability of anti-apoptotic 
molecules and therefore, chemotherapy resistance.
We also observed that when gal-3 is unable to bind 
extracellular ligands, because of increased sTn, gal-3 
accumulates in the intracellular milieu. This fact might 
contribute to the chemotherapeutic resistance observed 
in sTn overexpressing cells. Intracellular galectin-3 has 
been intensively studied as an anti-apoptotic molecule 
in response to chemotherapeutic drugs. It was shown 
that intracellular galectin-3 increased thyroid cancer 
cells resistance to doxorubicin by activating the PI3K 
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pathway [60]. Recently, Lu et al., described that galectin-3 
interaction with NF-kB pathway conferred resistance of 
ovarian cancer cell to carboplatin [61]. Moreover, in lung 
cancer cells, gal-3 silencing increased drug sensitivity 
to cisplatin and paclitaxel by regulating the ABCB1 and 
ABCG2 transporter pumps through β-catenin [62]. In the 
cytoplasm, galectin-3 heterodiimerzation with Bax was 
also found to protect cells against doxorubicin-induced 
apoptosis in thyroid carcinoma cells [63]. Therefore, these 
and other studies clearly demonstrate that an intracellular 
Figure 8: Expression of sialyl-Tn and galectin-3-binding sites in human gastric tumors A. Immunohistochemical staining 
of galectin-3, galectin-3-binding sites (hrGal-3/AP) and sialyl-Tn in human gastric tissue samples. B. Immunofluorescence of gastric tumor 
samples with galectin-3-Dy488, sialyl-Tn and DAPI staining. (A and B) Representative images are shown, bar=20 μm. See also Figure S5.
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accumulation of gal-3 can provide a resistance mechanism 
to drug-induced cell death.
Here we also observed that tumor cells displaying 
gal-3-binding sites increased their content of cell surface 
galectin-3 after cisplatin treatment and presented enhanced 
susceptibility to chemotherapeutic-induced cell death. 
One may suggest that increased levels of extracellular 
galectin-3 can account for the increased sensitivity to 
chemotherapeutics. Numerous studies have supported the 
concept that extracellular gal-3 alone is able to promote 
apoptosis in human leukemia T cell lines [64], human B 
cell lymphoma [65], neutrophils [66] and in a colon cancer 
cell model [42]. Though, in this study, exogenously added 
gal-3 alone did not induce tumor cell death but rather 
elicited chemotherapeutics-induced cell death in cells 
displaying gal-3-binding sites.
We believe that when tumor cells present 
extracellular galectin-3 binding sites, although galectin-3 
binding to the cell surface has no effect in the cell 
viability, its presence in the cell surface may interfere 
with cellular activation, regulating how cells respond to 
apoptotic stimulus. Several studies have suggested that 
galectin-3-glycoprotein lattices are capable of regulating 
the signaling threshold of a variety of cell surface 
receptors and to determine receptors residency time at 
the cell surface [67]. For example, galectin-3 lattice 
at the cell surface was found to reduce EGF receptor 
(EGFR) lateral mobility and internalization, and to 
increase EGFR signaling [68]. On the other hand, some 
reports have found a direct correlation between EGFR 
activation and enhanced sensitivity to cisplatin-induced 
cell death [69–71]. Although extracellular galectin-3 per 
se has no influence in cellular apoptosis, it’s binding to 
cell surface receptors such as EGFR can sensitize tumor 
cells to chemotherapeutics. We therefore suggest that the 
expression of sTn might be a mechanism to protect tumor 
cells from galectin-3 cell surface binding, thus preventing 
a cellular response to death-induced stimuli. Nevertheless, 
the specific regulation of cell surface receptors involved 
in apoptosis regulation by extracellular galectin-3 remains 
to be fully investigated and might depend not only on the 
cell type, but also on which receptors are present and its 
glycosylation status in a given cell.
Galectin-3 is well known to bind with high affinity 
to N-acetyllactosamine units, which are commonly found 
in the N- and O-glycans of glycoproteins. In this study 
Figure 9: Proposed model for sialyl-Tn mediated resistance to cisplatin. A. Tumor cells expressing galectin-3-binding sites 
also express galectin-3 at their cells surface. These cells are more susceptible to extracellular receptors clustering, caused by the action of 
extracellular galectin-3, thus increasing the sensitivity of tumor cells to cisplatin. B. Given that the apoptotic function of gal-3 is related to 
its subcellular location, tumor cells expressing sTn preferentially accumulate galectin-3 in the cytoplasm. As a consequence, sTn expressing 
cells are more resistant to chemotherapy and can activate the intracellular anti-apoptotic machinery.
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we have shown that despite the fact that ST6GalNAc-I-
overexpressing cells presented increased L-PHA-reactive 
MGAT5-modified N-glycans, preventing the extension 
of O-linked LacNAc residues with overexpression of 
ST6GalNAc-I led to reduced gal-3 cell surface binding. 
Moreover, although ST6GalNAc-I overexpressing 
cells display increased levels of ST6Gal-I mRNA, we 
demonstrated that ST6GalNAc-I knockdown had no 
interference with the expression of ST6Gal-I and was 
able to restore both gal-3-binding sites and cisplatin 
resistance. While these data suggest that ST6GalNAc-I 
overexpression and the consequent increase of sTn 
expression negatively regulates gal-3 cell surface 
recognition, we cannot rule out the contribution of 
others glycosyltransferases in regulating gal-3 cell 
surface binding. We hope that future studies may help 
to establish the role and contribution of each individual 
glyscosyltransferase involved in short O-glycans 
synthesis and its interference with galectin-3 subcellular 
localization.
In our study model, we also reported that the gal-
3C (which lacks the N-terminal domain responsible for 
oligomerization), alone or in combination with cisplatin 
or 5-FU, had no effect on gastric cancer cells viability. 
Galectin-3C was reported to act as a dominant negative 
inhibitor of extracellular gal-3 carbohydrate binding 
and to reduce tumor growth, motility, invasion and 
angiogenesis through inhibition of galectin-3 [72, 73]. 
Since the intracellular form of gal-3 accounts for the 
increased resistance to chemotherapy, it is not surprising 
that extracellular gal-3 inhibition by gal-3C had no effect 
on gastric cancer cells viability. Moreover, most of gal-
3 extracellular functions are mediated by its ability to 
oligomerize and crosslink cell surface proteins, therefore, 
one can assume that the sensitizing effect of gal-3 to 
chemotherapeutics may be dependent on gal-3-induced 
crosslink of cell surface receptors. We therefore propose 
a new mechanism by which sialyl-Tn influences tumor 
cell resistance to chemotherapeutic drugs (Figure 9). 
We believe that in a condition where tumor cells display 
gal-3-binding sites, extracellular gal-3 may form lattices 
with cell surface anti-apoptotic receptors, increasing their 
endocytosis and/or restricting their activation by apoptotic 
stimuli. On the other hand, in the presence of sTn two 
different mechanism may account for the increased 
drug resistance: (1) galectin-3 binding is inhibited and 
cell surface anti-apoptotic receptors can be activated in 
response to chemotherapeutic treatment; (2) levels of 
intracellular galectin-3 are increased, which is known to 
have an anti-apoptotic role.
Thus, the knowledge obtained from this study may 
open new perspectives in the way we diagnose and treat 
cancer. Indeed, a careful evaluation of sTn expression and 
galectin-3-binding sites in tumors may be important to 
predict patient’s response to a specific therapy. In addition, 
future therapies targeting galectin-3 and/or ST6GalNAc-I 
enzyme may include the design of RNA interference 
and/or explore sialyl-Tn expression for a selective drug-
delivery approach.
MATERIALS AND METHODS
Cell culture
MKN45-Mock and ST6GalNAc-I cells (American 
Type Culture Collection, Manassas, VALLC [74]) were 
cultured in RPMI (Gibco, Life technologies, MD, USA) 
supplemented with 10% of fetal bovine serum (Gibco, 
Life technologies, MD, USA), 50μg/mL of gentamicin 
(Gibco, Life technologies, MD, USA) and in the 
presence of geneticin (300μg/mL) (Sigma). Mycoplasma 
contamination in cultured cells was excluded by using 
Lonza Mycoplasma Detection Kit.
Stable transfections of full-length ST6GalNAc-I
Full length human ST6GalNAc-I vectors were 
prepared by PCR as previously reported [10]. Gastric 
carcinoma cell line MKN45 was transfected with 
plasmid pcDNA3.1/ST6GalNAc-I using the TFx-50 
reagent (Promega, Madison, WI). Cells were selected 
with 0.3 mg/mL of Geneticin for 2 weeks and resistant 
cells were cloned by the limiting dilution method [10]. 
ST6GalNAc-I expressing clones were screened by 
ST6GalNAc-I mRNA expression and by analysis of 
sialyl-Tn by flow cytometry.
Flow cytometry
For flow cytometry, cells were harvested and 
incubated with anti-sialyl-Tn (TKH2 antibody [75]), 
anti-galectin-3 (M3/38, ATCC TIB166), biotinylated 
lectins Erythrina cristagalli (ECA), Phaseolus vulgaris 
(L-PHA), Sambucus nigra (SNA) and Maackia amurensis 
(MAL) (from Vector Laboratories) or biotinylated-
Arachis hypogaea (PNA) (Sigma-Aldrich). Subsequently 
cells were washed with PBS, and primary antibodies 
were detected with anti-mouse-Alexa488 or anti-rat-
Alexa488 antibodies, or streptavidin-Alexa488 (all 
from Invitrogen) for 45 min. Alternatively, cells were 
incubated with DyLigth488 labelled-hrGal-3. For the 
cleaved caspase3/7 assay, cells were treated for 48h in the 
presence or absence of cisplatin (12,5μM). Caspase-3/-7 
evaluation was performed accordingly to manufacturer’s 
instructions (Vybrant FAM Caspase-3 and -7 Assay 
kit, Life Technologies). Analyses were made using the 
flow cytometer CyAn™ ADP Analyzer from Beckman 
Coulter. Data were subsequently evaluated with FlowJo 
vX 0.7 software. For detailed protocol see supplemental 
experimental procedures.
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Gene expression analysis
Total RNA from cell cultures or tumor tissue 
was isolated with Tri-Reagent (Sigma) according to 
the manufacturer’s instructions. Complementary DNA 
(cDNA) was synthesized using the High capacity 
cDNA RT kit (Applied Biosystems), according to the 
manufacturer’s protocols. Quantitative PCR analysis was 
performed in triplicate using the SensiMix SYBR No-
ROX kit (Bioline). Relative quantification was done using 
the ΔΔCt method normalizing to GAPDH gene expression 
(See Table S2 for primer detail).
ELISA
MKN45-Mock or –ST6GalNAc-I cells were 
cultured in RPMI supplemented with 10% of fetal bovine 
serum in the presence of cisplatin (12.5μM or 25μM) for 
48h. After this period, the cellular medium was collected 
and galectin-3 was quantified by ELISA according to the 
manufacturer’s procedure (ELISA galectin-3 Duo Set, 
R&D Systems).
Immunofluorescence
Cells or gastric cancer tissues were incubated with 
anti-sialyl-Tn (TKH2 antibody[75]), anti-galectin-3 
(M3/38, ATCC TIB166) or hrGal-3-DyLight488 and 
detected with anti-mouse-Alexa-546 (Invitrogen) or anti-
rat-Alexa488 (Invitrogen), respectively. Nuclei were 
stained with DAPI (4',6-diamidino-2-phenylindole). 
Pictures were taken using a fluorescent inverted 
microscope (Zeiss Axiovert 200M). For detailed protocol 
see supplemental experimental procedures.
Immunostaining
Sections from cancer specimens were obtained from 
patients with mucinous adenocarcinomas undergoing 
surgery at Hospital S. João, Medical Faculty (Porto, 
Portugal) between 1991 and 2009. Tissue fragments were 
immunostained with anti-sialyl-Tn antibody ((TKH2 
antibody [75]), anti-galectin-3 (M3/38, ATCC TIB166) or 
incubated with hrGal-3/AP [76]. The tissue were classified 
using a 0-to-3 scale: 0 for 0–5% positive tumor cells, 1 for 
6–50% positive tumor cells, 2 for >50% positive tumor 
cells. For detailed protocol see supplemental experimental 
procedures.
Statistical analysis
All data are expressed as the mean ± SEM of at 
least three independent experiments. Statistical analysis 
including t-test, one-way ANOVA and two-way ANOVA 
were done using GraphPad Prism 6.0 software. p < 0.05 
was considered statistically significant.
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